Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: An exploratory analysis

Ward, P.; Hecht, J. Randolph; Wang, He-Jing; Dichmann, Richard; Liem, André; Chan, D; Patel, Ravi; Hu, Edward H.L.; Tchekmedyian, N. S.; Wainberg, Zev A.; Naeim, Arash

doi:10.1016/j.jgo.2014.05.002

Cited by 14 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 57 studies, eleven were set in the US [4–14], eight in the UK [15–22], seven in the Netherlands [23–29], five in Hong Kong [30–34], four in Canada [35–38], two each in Norway, Korea, Australia and Japan [39–46] and other country settings included Spain, Germany, India, Malaysia, Singapore, Sweden and Turkey [47–54]. Some studies did not report their settings or were multinational or multicentre studies [55–60].…”

Section: Resultsmentioning

confidence: 99%

“…Studies were mostly published in the last 15–20 years and focussed narrowly on different interventions at specific stages of CRC. For example, the adverse events (AEs) of chemotherapy and survival (partial response) in metastatic CRC (mCRC) were the main condition of interest in several studies [14, 20, 36, 38, 44, 48–50, 56, 58, 59]. HSUVs associated with rectal cancer have been reported [7, 18, 23–25, 27, 52, 54].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of health state utility values for economic evaluation of colorectal cancer

Kim

Cairns

2016

Health Econ Rev

View full text Add to dashboard Cite

Cost-utility analyses undertaken to inform decision making regarding colorectal cancer (CRC) require a set of health state utility values (HSUVs) so that the time CRC patients spend in different health states can be aggregated into quality-adjusted life-years (QALY). This study reviews CRC-related HSUVs that could be used in economic evaluation and assesses their advantages and disadvantages with respect to valuation methods used and CRC clinical pathways. Fifty-seven potentially relevant studies were identified which collectively report 321 CRC-related HSUVs. HSUVs (even for similar health states) vary markedly and this adds to the uncertainty regarding estimates of cost-effectiveness. There are relatively few methodologically robust HSUVs that can be directly used in economic evaluations concerned with CRC. There is considerable scope to develop new HSUVs which improve on those currently available either by expanded collection of generic measures or by making greater use of condition-specific data, for example, using mapping algorithms.Electronic supplementary materialThe online version of this article (doi:10.1186/s13561-016-0115-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Systematic review of health state utility values for economic evaluation of colorectal cancer

Kim

Cairns

2016

Health Econ Rev

View full text Add to dashboard Cite

show abstract

“…However, treatment decision should rely on a more global evaluation than only comorbidities [13]. Several other clinical factors, such as cognitive decline, denutrition, or mobility disorders, are well-known predictors of frailty in elderly cancer patients [14]. A more precise screening of frailty through the development of specific geriatric oncology units is then required to efficiently improve the quality of care in this population [15,16].…”

Section: Discussionmentioning

confidence: 99%

How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real‐life practice? A study in a French teaching hospital

Gouverneur

Rouyer

Grelaud

et al. 2016

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Metastatic colorectal cancer (mCRC) is frequent among elderly patients. However, in the era of new targeted therapies, little is known about real-life mCRC treatment in this population. This study aimed to describe elderly mCRC patients and the current real-life treatment practices. mCRC patients aged ≥65 years were identified using the registry of multidisciplinary team meetings, mandatory for all cancer patients, held between January 1, 2013 and June 30, 2014 at the Bordeaux University Hospital. Data were collected from medical records using a standardized questionnaire. Treatment type was defined as follows: at least one anticancer medication administered vs. best supportive care (BSC). A total of 78 patients were included; median age was 74 years and the M/F sex ratio 1.6. Eleven patients (14.1%) were referred to a geriatric oncology consultation. One patient died before treatment initiation, 28 (35.9%) had BSC, and 49 (62.8%) were treated with anticancer medications: 20 (25.6%) had chemotherapy combined with a targeted therapy, and 28 (35.9%) chemotherapy alone (one missing data for treatment). Compared to patients treated with anticancer medications, BSC patients were older (P < 0.0001) and had more often metachronous metastases (P = 0.01), more comorbidities (P = 0.05), and a greater number of concomitant medications (P = 0.004). This study is one of the rare investigations providing insight to treatment practices in all elderly mCRC patients, not just those who receive anticancer medications. Our results suggest that efforts must be pursued to better integrate geriatric oncology in daily clinical practice.

show abstract

“…Most trials are focused on good PS patients (PS ECOG 0-1), and patients with suboptimal PS (ECOG 2) or poor PS (ECOG > 2) are underrepresented or not included in clinical trials. When these patients with suboptimal or poor PS are included, worse tolerance and efficacy are usually observed [8,9]. Because of that, trials specifically focused on this suboptimal or poor PS population should be performed.…”

Section: Age Comorbidities and Psmentioning

confidence: 99%

“…Firstly, CRC is a very heterogeneous disease, and subclassifications are required [35,52]. Also, age, PS, and comorbidities help to define the treatment strategy for many patients [7,9]. Regarding the question of carrying out surgery in the primary tumor, this procedure is not always required [13][14][15][16][17][18].…”

Section: Conclusion and Recommendationsmentioning

confidence: 99%

Current controversies in the management of metastatic colorectal cancer

Vera

Alonso

Gállego

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

The factors affecting the decisions for the treatment for patients with metastatic colorectal cancer (mCRC) are related to the patient, the tumor, and the treatment itself. Both cetuximab and panitumumab are anti-EGFR monoclonal antibody options for patients with RAS wild-type tumors. Several trials comparing these agents with bevacizumab are analyzed in this paper. The liver is the most common site of metastases in patients with CRC, and perioperative chemotherapy has been shown to yield benefits in this setting. In the second-line treatment for mCRC, maintenance with bevacizumab after progression following first-line treatment is convenient in some groups of patients with mCRC. Also, aflibercept has demonstrated benefits in response rate, progression-free survival, and overall survival in second-line treatment, whereas regorafenib provides benefits to patients progressing on all standard therapies. Several novel therapeutic options for patients with mCRC are under development, and these are discussed.

show abstract

Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: An exploratory analysis

Cited by 14 publications

References 28 publications

Systematic review of health state utility values for economic evaluation of colorectal cancer

Systematic review of health state utility values for economic evaluation of colorectal cancer

How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real‐life practice? A study in a French teaching hospital

Current controversies in the management of metastatic colorectal cancer

Contact Info

Product

Resources

About